It implies that maintaining the expression of YAP/TAZ, which can be implemented by YAP/TAZ/TEAD1 activators or inhibitors of upstream kinases (MST1/2, LATS1/2), maybe a potential target in future diabetes treatment. The gene discussed is TEAD1; the disease is diabetes mellitus.